Home In Interim Results from Phase 3 Study, Mercks Investigational Ebola Vaccine Efficacious; Study is Continuing
 

Keywords :   


In Interim Results from Phase 3 Study, Mercks Investigational Ebola Vaccine Efficacious; Study is Continuing

2015-07-31 14:10:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Global Collaboration Enabled Vaccine to Move from First-in-Human Studies to Initial Phase 3 Results Within One Year KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (known as MSD outside the US and Canada) said today that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3 ring vaccination trial in Guinea. Preliminary conclusions from this study, which is continuing, were published on-line today in The Lancet. Language: English Contact: MerckMedia Contacts:Pam Eisele, 267-305-3558orInvestor Contacts:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: is results study phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
08.11Tech giants dominate U.S. streaming platform market
08.11Warner Bros. Discovery adds 7.2 million DTC subscribers in 3Q 2024
08.11Polyurea-Based Lining is Key to GRE Pipeline Rehab Project in UAE
08.11Parents paying over the odds for baby milk, watchdog warns
08.11Sports fans driving global growth in streaming services
08.11TiVo OS footprint approaching one million activated Smart TVs
08.11The Entertainer axes new shops after Budget tax rise
08.11Hurricane Rafael Graphics
More »